Study Using a Genomic Predictor of Platinum Resistance to Guide Therapy in Stage IIIB/IV Non-Small Cell Lung Cancer
Status:
Terminated
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
In this trial, subjects with chemo-naive advanced non-small cell lung cancer (NSCLC) were
assigned to chemotherapy using a genomic-based predictor for platinum sensitivity. After an
amendment dated 1/25/2010, subjects with squamous cell NSCLC sensitive to cisplatin received
cisplatin/gemcitabine and if resistant to cisplatin received docetaxel/gemcitabine. Subjects
with non-squamous cell NSCLC sensitive to cisplatin received cisplatin/pemetrexed and if
resistant to cisplatin received pemetrexed/gemcitabine. The primary objective of this trial
was to prospectively validate the genomic-based prediction model through separate evaluation
of the one-year progression-free survival (PFS) of the cisplatin-sensitive and
cisplatin-resistant cohorts. Secondary objectives included: assessment of overall time to
progressive disease, quality of life and evaluation of drug sensitivity patterns of cisplatin
and pemetrexed.